Ex-Genmab medic joins Alligator as CMO; other appointments

Swedish biotech Alligator Bioscience (STO: ATORX) today announced the expansion of its management team with the appointment of Charlotte Russell as chief medical officer and Peter Ellmark as vice president discovery.

Dr Russell will be responsible for leading Alligator’s clinical team in progressing the company’s immuno-oncology projects towards proof of concept in cancer patients. Her near-term focus will be advancing the bispecific antibody drug candidate ATOR-1015 into clinical studies during 2018. Dr Russell is a board-certified specialist in hematology and internal medicine, and will join Alligator from her role as senior medical director at Danish biotech firm Genmab (OMX: GEN), assuming her new role on January 1, 2018.

Dr Ellmark is currently principal scientist at Alligator, and in his new role will lead Alligator’s efforts to establish novel concepts for tumor-directed immunotherapies and to build the Discovery pipeline. He will assume his new position from January 1, 2018.